Have a personal or library account? Click to login
Polycystic Ovary Syndrome as a systemic disease with multiple molecular pathways: a narrative review Cover

Polycystic Ovary Syndrome as a systemic disease with multiple molecular pathways: a narrative review

Open Access
|Nov 2018

References

  1. Al-Eisa E, Gabr SA, Alghadir AH. Effects of supervised aerobic training on the levels of anti-Mullerian hormone and adiposity measures in women with normo-ovulatory and polycystic ovary syndrome. J Pak Med Assoc 67, 499-507, 2017.
  2. Arner P. Human fat cell lipolysis: biochemistry, regulation and clinical role. Best Pract Res Clin Endocrinol Metab 19, 471-482, 2005.10.1016/j.beem.2005.07.00416311212
  3. Artimani T, Karimi J, Mehdizadeh M, Yavangi M, Khanlarzadeh E, Ghorbani M, Asadi S, Kheiripour N. Evaluation of pro-oxidant-antioxidant balance (PAB) and its association with inflammatory cytokines in polycystic ovary syndrome (PCOS). Gynecol Endocrinol 34, 148-152, 2018.10.1080/09513590.2017.13716912886894328868943
  4. Aytan AN, Bastu E, Demiral I., Blulut H, Dogan M, Buyru F. Relationship between hyperandrogenism, obesity, inflammation and polycystic ovary syndrome. Gynecol Endocrinol 32, 709-713, 2016.10.3109/09513590.2016.115520826951881
  5. Azziz R, Marin C, Hoq L, Badamgarav E, Song P. Health care-related economic burden of the polycystic ovary syndrome during the reproductive life span. J Clin Endocrinol 90, 4650-4658, 2005.10.1210/jc.2005-062815944216
  6. Azziz R. Polycystic Ovary Syndrome Is a Family Affair. J Clin Endocrinol Metab 93, 1579-1581, 2008.10.1210/jc.2008-047718463352272918218463352
  7. Azziz R, Carmina E, Chen Z, Dunaif A, Laven JS, Legro RS, Lizneva D, Natterson-Horowtiz B, Teede HJ, Yildiz BO. Polycystic ovary syndrome. Nat Rev Dis Primers 2, 16057, 2016.10.1038/nrdp.2016.5727510637
  8. Bachanek M, Abdalla N, Cendrowski K, Sawicki W. Value of ultrasonography in the diagnosis of polycystic ovary syndrome - literature review. J Ultrason 15, 410-422, 2015.10.15557/JoU.2015.0038471069226807298
  9. Bachelot A. Polycystic ovarian syndrome: clinical and biological diagnosis. Ann Biol Clin Ann Biol Clin (Paris) 74, 661-667, 2016.10.1684/abc.2016.118427848917
  10. Bagatini SR. Polimorfismos do gene da adiponectina e variaveis clinicas, metabolicas e hormonais em mulheres com ousem a sindrome dos ovarios policisticos (PCOS) e a investigacao de um modelo animal para o estudo da PCOS. Doctoral thesis - Physiology Program - Universidade Federal do Rio Grande do Sul. Porto Alegre, Rio Grande do Sul, 2010.
  11. Barbosa-Desongles A, Hernandez C, Simo R, Selva DM. Testosterone induces cell proliferation and cell cycle gene overexpression in human visceral preadipocytes. Am J Physiol Cell Physiol 305, C355-C359, 2013.10.1152/ajpcell.00019.201323720021
  12. Bartha JL, Comino-Delgado R, Romero-Carmona R, Gomez-Jaen MC. Sex hormone-binding globulin in gestational diabetes. Acta Obstet Gynecol Scand 79, 839-845, 2000.1130496610.3109/00016340009169212
  13. Birukov KG. Oxidized lipids: the two faces of vascular inflammation. Curr Atheroscler Rep 8, 223-231, 2006.1664095910.1007/s11883-006-0077-x16640959
  14. Burchall GF, Piva TJ, Linden MD, Gibson-Helm ME, Ranasinha S, Teede HJ. Comprehensive assessment of the hemostatic system in polycystic ovarian syndrome. Semin Thromb Hemost 42, 55-62, 2016.10.1055/s-0035-156483726595150
  15. Burt Solorzano CM, Beller JP, Abshire MY, Collins JS, McCartney CR, Marshall JC. Neuroendocrine dysfunction in polycystic ovary syndrome. Steroids 77, 332-337, 2012.10.1016/j.steroids.2011.12.007345352822172593
  16. Burtis CA, Ashwood EA, Tietz BD. Fundamentos de Quimica Clinica, 6ed. Filadelfia: Saunders, pp. 984, 2008.
  17. Carvalho LML, Ferreira CN, Soter MO, Sales MF, Rodrigues KF, Martins SR, Candido AL, Reis FM, Silva IFO, Campos FMF, Gomes KB. Microparticles: Inflammatory and haemostatic biomarkers in Polycystic Ovary Syndrome. Mol Cell Endocrinol 443, 155-162, 2017a.10.1016/j.mce.2017.01.01728088464
  18. Carvalho LML, Ferreira CN, De Oliveira DKD, Rodrigues KD, Duarte RCF, Teixeira MFA, Xavier LB, Candido AL, Reis FM, Silva IFO, Campos FMF, Gomes KB. Haptoglobin levels, but not Hp1-Hp2 polymorphism, are associated with polycystic ovary syndrome. J Assist Reprod Genet 34, 1691-1698, 2017b.10.1007/s10815-017-1030-3571482228900795
  19. Carvalho LML, Ferreira CN, Candido AL, Reis FM, Soter MO, Sales MD, Silva IFO, Nunes FC, Gomes KB. Metformin reduces total microparticles and microparticles-expressing tissue factor in women with polycystic ovary syndrome. Arch Gynecol Obstet 296, 617-621, 2017c.10.1007/s00404-017-4471-028795250
  20. Chang HM, Klausen C, Leung PCK. Antimullerian hormone inhibits follicle-stimulating hormone-induced adenylyl cyclase activation, aromatase expression, and estradiol production in human granulosa-lutein cells. Fertil Steril 100, 585-592, 2013.10.1016/j.fertnstert.2013.04.01923663993
  21. Chen J, Shen S, Tan Y, Xia D, Cia Y, Cao Y, Cao Y, Wang W, Wu X, Wang H, Yi L, Gao Q, Wang Y. The correlation of aromatase activity and obesity in women with or without polycystic ovary syndrome. J Ovarian Res 22, 11, 2015.10.1186/s13048-015-0139-1439274925881575
  22. Cimino I, Casoni F, Liu X. Novel role for anti-Mullerian hormone in the regulation of GnRH neuron excitability and hormone secretion. Nat Commun 7, 10055, 2016.10.1038/ncomms10055472992426753790
  23. De Leo V, Musacchio MC, Cappelli V, Massaro MG, Morgante G, Petraglia F. Genetic, hormonal and metabolic aspects of PCOS: an update. Reprod Biol Endocrinol 14, 38, 2016.10.1186/s12958-016-0173-x494729827423183
  24. Deligeoroglou E, Vrachnis N, Athanasopoulos N, Iliodromiti Z, Sifakis S, Iliodromiti S, Siristatidis C, Creatsas G. Mediators of chronic inflammation in polycystic ovarian syndrome. Gynecol Endocrinol, 28, 974-978, 2012.10.3109/09513590.2012.6830822255398322553983
  25. Delitala AP, Capobianco G, Delitala G, Cherchi PL, Dessole S. Polycystic ovary syndrome, adipose tissue and metabolic syndrome. Arch Gynecol Obstet 296, 405-419, 2017.10.1007/s00404-017-4429-228643028
  26. Deswal R, Yadav A, Dang AS. Sex hormone binding globulin - an important biomarker for predicting PCOS risk: A systematic review and meta-analysis. Syst Biol Reprod Med 64, 12-24, 2018.10.1080/19396368.2017.141059129227165
  27. Diamanti-Kandarakis E, Papavassiliou AG, Kandrarakis SA, Chrousos GP. Focus on Polycystic Ovary Syndrome pathophysiology and types of dyslipidemia in PCOS. Trends Endocrinol Metab 19, 280-285, 2007.10.1016/j.tem.2007.07.00417692530
  28. Di Segni C, Silvestrini A, Fato R, Bergamini C, Guidi F, Raimondo S, Meucci E, Romualdi D, Apa R, Lanzone A, Mancini A. Plasmatic and intracellular markers of oxidative stress in normal weight and obese patients with Polycystic Ovary Syndrome. Exp Clin Endocrinol Diabetes 125, 506-513, 2017.10.1055/s-0043-11124128675914
  29. Duleba AJ, Dokras A. Is PCOS an inflammatory process? Fertil Steril 97, 7-12, 2012.2219213510.1016/j.fertnstert.2011.11.023324582922192135
  30. Dumesic DA, Akopians AL, Madrigal VK. Hyperandrogenism accompanies increased intra-abdominal fat storage in normal weight Polycystic Ovary Syndrome women. J Clin Endocrinol Metab 101, 4178-4188, 2016.10.1210/jc.2016-2586509524327571186
  31. Dumont A, Robin G, Catteau-Jonard S, Dewailly D. Role of anti-Mullerian hormone in pathophysiology, diagnosis and treatment of Polycystic Ovary Syndrome: a review. Reprod Biol Endocrinol 13, 137, 2015.10.1186/s12958-015-0134-9468735026691645
  32. Dunaif A. Perspectives in Polycystic Ovary Syndrome: From hair to eternity. J Clin Endocrinol Metab 101, 759-768, 2016.10.1210/jc.2015-3780480316126908109
  33. Echiburu B, Perez-Bravo F, Galgani JE, Sandoval D, Saldias C, Crisosto N, Maliqueo M, Sir-Petermann T. Enlarged adipocytes in subcutaneous adipose tissue associated to hyperandrogenism and visceral adipose tissue volume in women with polycystic ovary syndrome. Steroids 130, 15-21, 2018.10.1016/j.steroids.2017.12.00929273198
  34. Eder K, Baffy N, Falus A, Fulop AK. The major inflammatory mediator interleukin-6 and obesity. Inflamm Res 58, 727-736, 2009.10.1007/s00011-009-0060-41954369119543691
  35. Escobar-Morreale HF, San Millan JL. Abdominal adiposity and the polycystic ovary syndrome. Trends Endocrinol Metab 18, 266-272, 2007.10.1016/j.tem.2007.07.00317693095
  36. Faghfoori Z, Fazelian S, Shadnoush M, Goodarzi R. Nutritional management in women with polycystic ovary syndrome: A review study. Diabetes Metab Syndr 11, 429-432, 2017.10.1016/j.dsx.2017.03.03028416368
  37. Fan W, Li S, Chen Q, Huang Z. Association between the (TAAAA)n SHBG polymorphism and PCOS: a systematic review and meta-analysis. Gynecol Endocrinol 29, 645-650, 2013.10.3109/09513590.2013.79739423772775
  38. Fonseca-Alaniz MH, Takada J, Alonso-Vale MI, Lima FB. Adipose tissue as an endocrine organ: from theory to practice. J Pediatr 83, 192-203, 2007.10.1590/S0021-75572007000700011
  39. Foroozanfard F, Jamilian M, Bahmani F, Talaee R, Talaee N, Hashmi T, Nasri K, Asemi Z, Esmaillzadeh A. Calcium plus vitamin D supplementation influences biomarkers of inflammation and oxidative stress in overweight and vitamin D-deficient women with polycystic ovary syndrome: a randomized double-blind placebo-controlled clinical trial. Clin Endocrinol 83, 888-894, 2015.10.1111/cen.1284026119844
  40. Ghafurniyan H, Azarnia M, Nabiuni M, Karimzadeh L. The effect of green tea extract on reproductive improvement in estradiol valerate-induced polycystic ovary Polycystic Ovarian Syndrome in rat. Iran J Pharm Res 14, 1215-1233, 2015.26664389
  41. Glintborg D, Andersen M. Management of endocrine disease: morbidity in polycystic ovary syndrome. Eur J Endocrinol 176, R53-R65, 2017.10.1530/EJE-16-037327601016
  42. Gonzalez F, Rote NS, Minium J, Kirwan JP. Reactive oxygen species-induced oxidative stress in the development of insulin resistance and hyperandrogenism in polycystic ovary syndrome. J Clin Endocrinol Metab 91, 336-340, 2006.1624927910.1210/jc.2005-169616249279
  43. Gonzalez F, Kirwan JP, Rote NS, Minium J. Elevated circulating levels of tissue factor in polycystic ovary syndrome. Clin Appl Thromb Hemost 19, 66-72, 2013.10.1177/107602961243667322327820
  44. Goodarzi MO, Shah NA, Antoine HJ, Pall M, Guo X, Azziz R. Variants in the 5alpha-reductase type 1 and type 2 genes are associated with polycystic ovary syndrome and the severity of hirsutism in affected women. J Clin Endocrinol Metab 91, 4085-4091, 2006.10.1210/jc.2006-022716849416
  45. Green A, Rumberger JM, Stuart CA, Ruhoff MS. Stimulation of lipolysis by tumor necrosis factor-alpha in 3T3-L1 adipocytes is glucose dependent: implications for long-term regulation of lipolysis. Diabetes 53, 74-81, 2004.10.2337/diabetes.53.1.7414693700
  46. Groth SW. Adiponectin and polycystic ovary syndrome. Biol Res Nurs 12, 62-72, 2010.10.1177/1099800410371824364651920498127
  47. Hosseini AH, Kohan L, Aledavood A, Rostami S. Association of miR-146a rs2910164 and miR-222 rs2858060 polymorphisms with the risk of polycystic ovary syndrome in Iranian women: A case-control study. Taiwan J Obstet Gynecol 56, 652-656, 2017.10.1016/j.tjog.2017.08.01429037553
  48. Insenser M, Martinez-Garcia MA, San-Milan JL, Escobar-Morreale HF. Proteomic analysis of plasma in the Polycystic Ovary Syndrome identifies novel markers involved in iron metabolism, Acute-Phase Response, and Inflammation. J Clin Endocrinol Metab 95, 3863-3870, 2010.10.1210/jc.2010-022020484478
  49. Insenser M, Escobar-Morreale. Proteomics and polycystic ovary syndrome. Expert Rev Proteomics 10, 435-447, 2013.10.1586/14789450.2013.83766524087928
  50. Jayasena C, Franks S. The management of patients with polycystic ovary syndrome. Nature Reviews Endocrinology 10, 624-636, 2014.2502281410.1038/nrendo.2014.10225022814
  51. Jakimiuk AJ, Weitsman SR, Magoffin DA. 5alpha-reductase activity in women with polycystic ovary syndrome. J Clin Endocrinol Metab 84, 2414-2418, 1999.10.1210/jc.84.7.2414
  52. Jalilian A, Kiani F, Sayehmiri F, Sayehmiri K, Khodaee Z, Akbari M. Prevalence of polycystic ovary syndrome and its associated complications in Iranian women: A meta-analysis. Iran J Reprod Med 13, 591-604, 2015.26644787
  53. Jia H, Yu L, Guo X, Gao W, Jiang Z. Associations of adiponectin gene polymorphisms with polycystic ovary syndrome: a meta-analysis. Endocrine 42, 299-306, 2012.10.1007/s12020-012-9605-32227087222270872
  54. Jiao J, Fang Y, Wang T, Wang Z, Zhuou M, Wang X. Epidemiologic investigation of polycystic ovarian syndrome (PCOS) in Han ethnic women of reproductive age in Liaoning Province, China. Clin Exp Obstet Gynecol 41, 304-309, 2014.2499278210.12891/ceog16282014
  55. Joham AE, Teede HJ, Ranasinha S, Zoungas S, Boyele J. Prevalence of infertility and use of fertility treatment in women with polycystic ovary syndrome: data from a large community-based cohort study. J Womens Health (Larchmt) 24, 299-307, 2015.10.1089/jwh.2014.500025654626
  56. Kahsar-Miller M, Azziz R. The development of the polycystic ovary syndrome: family history as a risk factor. Trends Endocrinol Metab 9, 55-58, 1998.10.1016/S1043-2760(98)00021-6
  57. Karakas SE. New biomarkers for diagnosis and management of polycystic ovary syndrome. Clin Chim Acta. 471, 248-253, 2017.10.1016/j.cca.2017.06.009
  58. Koiou E, Tziomalos K, Katsikis I, Dinas K, Tsourdi EA, Delkos D, Papadakis E, Panidis D. Plasma Von Willebrand factor antigen levels are elevated in the classic phenotypes of polycystic ovary syndrome. Hormones 11, 77-85, 2012.2245034710.1007/BF03401540
  59. Kopelman PG. Obesity as a medical problem. Nature 404, 635-643, 2000.10.1038/35007508
  60. Kristiansen SB, Endoh A, Casson PR, Buster JE, Hornsby PJ. Induction of steroidogenic enzyme genes by insulin and IGF-I in cultured adult human adrenocortical cells. Steroids 62, 258-265, 1997.10.1016/S0039-128X(96)00223-19055386
  61. Kurobe FMC, Dzik A, Cavagna M, Drezett J. Importancia do hormonio anti-Mullerian on a infertilidade. Reprod Clim 27 104-108, 2012.10.1016/j.recli.2013.03.003
  62. Lamanna C, Monami M, Marchionni N, Mannucci EE. Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 13, 221-228, 2011.2120512110.1111/j.1463-1326.2010.01349.x21205121
  63. Langin D. Control of fatty acid and glycerol release in adipose tissue lipolysis. C R Biol 329, 598-607, 2006.10.1016/j.crvi.2005.10.00816860278
  64. Lehr S, Hartwig S, Sell H. Adipokines: A treasure trove for the discovery of biomarkers for metabolic disorders. Proteomics Clin Appl 6, 91-101, 2012.2221362710.1002/prca.20110005222213627
  65. Liu Y, Nair MG. An efficient and economical MTT assay for determining the antioxidant activity of plant natural product extracts and pure compounds. J Nat Prod 73, 1193-1195, 2010.10.1021/np100094520565070
  66. Liu H, Zhao H, Chen ZJ. Genome-wide association studies for Polycystic Ovary Syndrome. Semin Reprod Med 34, 224-229, 2016.10.1055/s-0036-158540327513023
  67. Mackman N. The role of tissue factor and factor VIIa in hemostasis. Anesth Analg 108, 1447-1452, 2009.10.1213/ane.0b013e31819bceb1283871319372318
  68. Macut D, Damjanovic S, Panidis D, Spanos N, Glisic B, Petakov M, Rousso D, Kourtis A, Bjekic J, Milic N. Oxidised low-density lipoprotein concentration - early marker of an altered lipid metabolism in young women with PCOS. Eur J Endocrinol 155, 131-136, 2006.10.1530/eje.1.0218716793959
  69. Macut D, Bjekic-Macut J, Savic-Radojevic A. Dyslipidemia and oxidative stress in PCOS. Front Horm Res 40, 51-63, 2013.10.1159/00034168324002405
  70. Magoffin DA. Ovarian theca cell. Int J Biochem Cell Biol 37, 1344-1349, 2005.10.1016/j.biocel.2005.01.01615833266
  71. Mahde A, Shaker M, Al-Mashhadani Z. Study of Omentin1 and Other Adipokines and Hormones in PCOS Patients. Oman Med J 24, 108-18, 2009.
  72. Maliqueo M, Sun M, Johansson J, Benrick A, Labrie F, Svensson H, Lonn M, Duleba AJ, Stener-Victorin E. Continuous administration of a P450 aromatase inhibitor induces Polycystic Ovary Syndrome with a metabolic and endocrine phenotype in female rats at adult age. Endocrinology 154, 434-445, 2013.10.1210/en.2012-169323183180
  73. Manneras-Holm L, Baghaei F, Holm G, Janson PO, Ohlsson C, Lonn M, Stener-Victorin E. Coagulation and fibrinolytic disturbances in women with polycystic ovary syndrome. J Clin Endocrinol Metab 96, 1068-1076, 2011.10.1210/jc.2010-227921252248
  74. Matharoo-Ball B, Hughes C, Lancashire L, Tooth D, Ball G, Creaser C, Elgasim M, Rees R, Layfield R, Atiomo W. Characterization of biomarkers in polycystic ovary syndrome (PCOS) using multiple distinct proteomic platforms. J Proteome Res 6, 3321-3328, 2007.10.1021/pr070124b17602513
  75. Mesri M, Altieri DC. Endothelial cell activation by leukocyte microparticles. J Immunol 161, 4382-4387, 1998.10.4049/jimmunol.161.8.4382
  76. Miller VM, Lahr BD, Bailey KR, Hodis HN, Mulvagh SL, Jayachandran M. Specific cell-derived microvesicles: Linking endothelial function to carotid artery intima-media thickness in low cardiovascular risk menopausal women. Atherosclerosis 246, 24-28, 2016.10.1016/j.atherosclerosis.2015.12.030476446126752689
  77. Mirza SS, Shafique K, Shaikh AR, Khan NA, Anwar Qureshi M. Association between circulating adiponectin levels and polycystic ovarian syndrome. J Ovarian Res 7, 18, 2014.10.1186/1757-2215-7-18392832024502610
  78. Mombaini E, Jafarirad S, Husain D, Haghighizadeh MH, Padfar P. The impact of green tea supplementation on anthropometric indices and inflammatory cytokines in women with Polycystic Ovary Syndrome. Phytother Res 31, 747-754, 2017.2824461210.1002/ptr.5795
  79. Moran LJ, Hutchison SK, Meyer C, Zoungas S, Teede HJ. A comprehensive assessment of endothelial function in overweight women with and without polycystic ovary syndrome. Clin Sci 116, 761-770, 2009.10.1042/CS20080218
  80. Morgante G, Cappelli V, Di Sabatino A, Massaro MG, De Leo V. Polycystic ovary syndrome (PCOS) and hyperandrogenism: the role of a new natural association. Minerva Ginecol 67, 457-463, 2015.
  81. Mortada R, Kallail KJ, Dong F, Karakas S. HbA1c in Patients with Polycystic Ovary Syndrome: A Potential Marker of Inflammation. J Reprod Infertil 16, 203-206, 2015.
  82. Murri M, Luque-Ramirez M, Insenser M, Ojeda-Ojeda M, Escobar-Morreale HF. Circulating markers of oxidative stress and polycystic ovary syndrome (PCOS): a systematic review and meta-analysis. Hum Reprod Update 19, 268-288, 2013.10.1093/humupd/dms05923303572
  83. Musmar S, Afaneh A, Mo’alla H. Epidemiology of polycystic ovary syndrome: a cross sectional study of university students at An-Najah national university-Palestine. Reprod Biol Endocrinol 11, 47, 2013.10.1186/1477-7827-11-47
  84. Nahum R, Thong KJ, Hillier SG. Metabolic regulation of androgen production by human thecal cells in vitro. Hum Reprod 10, 75-81, 1995.774507410.1093/humrep/10.1.75
  85. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106, 3143-3421, 2002.10.1161/circ.106.25.3143
  86. Nestler JE, Powers LP, Matt DW, Steingold KA, Plymate SR, Rittmaster RS, Clore JN, Blackard WG. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab 72, 83-89, 1991.10.1210/jcem-72-1-83
  87. Nielsen S, Karpe F. Determinants of VLDL-triglycerides production. Curr Opin Lipidol 29, 321-326, 2012.10.1097/MOL.0b013e3283544956
  88. Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syndrome. Lancet 370, 385-397, 2007.10.1016/S0140-6736(07)61345-2
  89. Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol 11, 85-97, 2011.10.1038/nri292121252989351803121252989
  90. Ozer A, Bakacak M, Kıran H, Ercan O, Kostu B, Kanat-Pektaş M, Kilinc M, Aslan F. Increased oxidative stress is associated with insulin resistance and infertility in polycystic ovary syndrome. Ginekol Pol 87, 733-738, 2016.10.5603/GP.2016.007927958630
  91. Palomba S, Falbo SSA, La Sala GB. Complications and challenges associated with polycystic ovary syndrome: current perspectives. Int J Womens Health 7, 745-763, 2015.10.2147/IJWH.S70314452756626261426
  92. Papadakis G, Kandaraki E, Papalou O, Vryonidou A, Diamanti-Kandarakis E. Is cardiovascular risk in women with PCOS a real risk? Current insights. Minerva Endocrinol 42, 340-355, 2017.2814613910.23736/S0391-1977.17.02609-828146139
  93. Pavaleanu I, Gafitanu D, Popovici D, Duceac LD, Pavaleanu M. Treatment of metabolic alterations in Polycystic Ovary Syndrome. Rev Med Chir Soc Med Nat Iasi 120, 258-263, 2016.
  94. Peng Z, Sun Y, Lv X, Zhang H, Liu C, Dai S. Interleukin-6 levels in women with Polycystic Ovary Syndrome: A systematic review and meta-analysis. PLoS One 11, e0148531, 2016.10.1371/journal.pone.0148531474612226849353
  95. Quinn MM, Kao CN, Ahmad AK, Haisenleder DJ, Santoro N, Eisenberg E, Legro RS, Cedars MI, Huddleston HG. Age-stratified thresholds of anti-Mullerian hormone improve prediction of polycystic ovary syndrome over a population-based threshold. Clin Endocrinol 87, 733-740, 2017.10.1111/cen.1341528681949
  96. Razavi M, Jamilian M, Karamali M, Bahmani F, Aghadovod E, Asemi Z. The effects of vitamin D-K-calcium co-supplementation on endocrine, inflammation, and oxidative stress biomarkers in vitamin D-deficient women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Horm Metab Res 48, 446-451, 2016.2705025210.1055/s-0042-10406027050252
  97. Reddy TV, Govatati S, Deenadayal M, Shivaji S, Bhanoori M. Polymorphisms in the TFAM and PGC1-α genes and their association with polycystic ovary syndrome among South Indian women. Gene 641, 129-136, 2018.10.1016/j.gene.2017.10.01029030253
  98. Reis GVOP, Gontijo NA, Rodrigues KF, Alves MT, Ferreira CN, Gomes KB. Vitamin D receptor polymorphisms and the polycystic ovary syndrome: A systematic review. J Obstet Gynaecol Res 43, 436-446, 2017.10.1111/jog.1325028127831
  99. Repaci A, Gambineri A, Pasquali R. The role of low-grade inflammation in the polycystic ovary syndrome. Mol Cell Endocrinol 335, 30-41, 2011.10.1016/j.mce.2010.08.00220708064
  100. Rittmaster RS, Deshwal N, Lehman L. The role of adrenal hyperandrogenism, insulin resistance, and obesity in the pathogenesis of polycystic ovarian syndrome. J Clin Endocrinol Metab 76, 1295-1300, 1993.838840510.1210/jcem.76.5.83884058388405
  101. Rocha MP, Maranhao RC, Maranhao RC, Seydell TM, Barcellos CRG, Baracat EC, Hayashida SAY, Bydlowski SP, Marcondes JAM. Metabolism of triglyceride-rich lipoproteins and lipid transfer to high-density lipoprotein in young obese and normal-weight patients with polycystic ovary syndrome. Fertil Steril 93, 1948-1956, 2010.10.1016/j.fertnstert.2008.12.04419765700
  102. Rojas J, Chavez M, Olivar L, Rojas M, Morillo J, Mejias J, Calvo M, Bermudez V. Polycystic ovary syndrome, insulin resistance, and obesity: navigating the pathophysiologic labyrinth. Int J Reprod Med 2014, 719050, 2014.2576340510.1155/2014/719050433407125763405
  103. Rosenfield RL, Ehrmann DA. The pathogenesis of Polycystic Ovary Syndrome (PCOS): The hypothesis of PCOS as functional ovarian hyperandrogenism revisited. Endocr Rev 37, 467-520, 2016.10.1210/er.2015-1104504549227459230
  104. Ruan Y, Ma J, Xie X. Association of IRS-1 and IRS-2 genes polymorphisms with polycysticovary syndrome: a metaanalysis. Endocr J 59, 601-619, 2012.10.1507/endocrj.EJ11-0387
  105. Sales MF, Soter MO, Candido AL, Fernandes AP, Oliveira FR, Ferreira ACS, Souza MO, Ferreira CN, Gomes KB. Correlation between plasminogen activator inhibitor-1 (PAI-1) promoter 4G/5G polymorphism and metabolic/ proinflammatory factors in polycystic ovary syndrome. Gynecol Endocrinol 29, 936-939, 2013.10.3109/09513590.2013.81908623898913
  106. Sam S. Obesity and Polycystic Ovary Syndrome. Obes Manag 3, 69-73, 2007.10.1089/obe.2007.0019286198320436797
  107. Santos LC, Torrent IF. O tecido adiposo e a producao de adipocinas. Synthesis Revista Digital FAPAM 2, 110-119, 2010.
  108. Sarray S, Madan S, Saleh LR, Mahmoud N, Almawi WY. Validity of adiponectin-to-leptin and adiponectin-to-resistin ratios as predictors of polycystic ovary syndrome. Fertil Steril 104, 460-466, 2015.10.1016/j.fertnstert.2015.05.00726051098
  109. Seyfart T, Friedrich N, Kische H, Bulow R, Wallaschofski H, Volzke H, Nauck M, Keevil BG, Haring R. Association of sex hormones with physical, laboratory, and imaging markers of anthropometry in men and women from the general population. PLoS One 13, e0189042, 2018.2932478710.1371/journal.pone.0189042576423329324787
  110. Shen CC, Yang AC, Hung J, Hu LY, Tsai SJ. A nationwide population-based retrospective cohort study of the risk of uterine, ovarian and breast cancer in women with polycystic ovary syndrome. Oncologist 20, 45-49, 2015.10.1634/theoncologist.2014-0311429461425410097
  111. Silva FS, Soter MO, Sales MF, Candido AL, Reis FM, Silva IFO, Souza MO, Ferreira CN, Gomes KB. Estrogen receptor α lpha gene (ESR1) Pvu II and Xba I polymorphisms are associated to metabolic and proinflammatory factors in polycystic ovary syndrome. Gene 560, 44-49, 2015.10.1016/j.gene.2015.01.03725617525
  112. Skalba P, Dabkowska-Huc A, Kazimierczak W, Samojedny A, Samojedny MP, Chelmicki Z. Content of 5-alphareductase (type 1 and type 2) mRNA in dermal papillae from the lower abdominal region in women with hirsutism. Clin Exp Dermatol 31, 564-570, 2006.10.1111/j.1365-2230.2006.02146.x16716164
  113. Song GJ, Kim SM, Park KH, Kim J, Choi I, Cho KH. SR-BI mediates high density lipoprotein (HDL)-induced antiinflammatory effect in macrophages. Biochem Biophys Res Commun 457, 112-118, 2015.10.1016/j.bbrc.2014.12.02825528585
  114. Soter MO, Ferreira CN, Sales MF, Candido AL, Reis FM, Milagres KS, Ronda C, Silva IO, Sousa MO, Gomes KB. Peripheral blood-derived cytokine gene polymorphisms and metabolic profile in women with polycystic ovary syndrome. Cytokine 76, 227-235, 2015.10.1016/j.cyto.2015.06.00826141422
  115. Spritzer PM, Poy M, Wiltgen D, Mylius LS, Capp E. Leptin concentrations in hirsute women with polycystic ovary syndrome or idiopathic hirsutism: influence on LH and relationship with hormonal, metabolic, and anthropometric measurements. Hum Reprod 16, 1340-1346, 2001.10.1093/humrep/16.7.13401142581011425810
  116. Targuer G, Zoppini G, Bonora E, Moghetti P. Hemostatic and fibrinolytic abnormalities in polycystic ovary syndrome. Semin Thromb Hemost 40, 600-618, 2014.10.1055/s-0034-138451225000958
  117. Tata B, Mimouni NEH, Barbotin AL, Malone SA, Loyens A, Pigny P, Dewailly D, Catteau-Jonard S, Sundstrom- Poromaa I, Piltonen TT, Dal Bello F, Medana C, Prevot V, Clasadonte J, Giacobini P. Elevated prenatal anti- Mullerian hormone reprograms the fetus and induces polycystic ovary syndrome in adulthood. Nat Med 24, 834-846, 2018.2976044510.1038/s41591-018-0035-5609869629760445
  118. Tehrani FR, Simbar M, Tohidi M, Hosseinpanah F, Azizi F. The prevalence of polycystic ovary syndrome in a community sample of Iranian population: Iranian PCOS prevalence study. Reprod Biol Endocrinol 9, 39, 2011.10.1186/1477-7827-9-39307063221435276
  119. Thathapudi S, Kodati V, Raj AY, Addepallyn U, Katragadda A, Hasan Q. Role of TNF α in the etiopathogenesis of PCOS: a clinical, biochemical and molecular genetic study. Mol Cytogenet 7, 94, 2014.10.1186/1755-8166-7-S1-P94
  120. Unluturk U, Sezgin E, Yildiz BO. Evolutionary determinants of polycystic ovary syndrome-part 1. Fertil Steril 106, 33-41, 2016.10.1016/j.fertnstert.2016.05.01027238626
  121. Van-Hall G, Stennsberg A, Sacchetti M, Fischer C, Keeller C, Schjerling P, Hiscock N, Moller K, Saltin B, Febbraio MA, Pedersen BK. Interleukin-6 stimulates lipolysis and fat oxidation in humans. J Clin Endocrinol Metab 88, 3005-3010, 2003.10.1210/jc.2002-02168712843134
  122. Vassiliadi DA, Barber TM, Hughes BA, McCarthy MI, Wass JA, Franks S, Nightingale P, Tomlinson JW, Arlt W, Stewart PM. Increased 5 alpha-reductase activity and adrenocortical drive in women with polycystic ovary syndrome. J Clin Endocrinol Metab 94, 3558-3566, 2009.1956751810.1210/jc.2009-083719567518
  123. Vink JM, Ssadzadeh S, Lambalk CB, Boomsma DI. Heritability of Polycystic Ovary Syndrome in a Dutch Twin- Family Study. J Clin Endocrinol Metab 91, 2100-2104, 2006.10.1210/jc.2005-149416219714
  124. Vodo S, Bechi N, Petroni A, Muscoli C, Aloisi AM. Testosterone-induced effects on lipids and inflammation. Mediators Inflamm 2013, 1-8, 2013.10.1155/2013/183041362821323606790
  125. Vrbikova J, Dvorakova K, Hill M, Vcelak J, Stanicka S, Vankova M, Sramkova D, Vondra K, Bendlova B, Starka L. Determinants of circulating adiponectin in women with polycystic ovary syndrome. Gynecol Obstet Invest 60, 155-161, 2005.10.1159/0000862731594224815942248
  126. Vural P, Degirmencioglu S, Saral NY, Akgul C. Tumor necrosis factor alpha (-308), interleukin-6 (-174) and interleukin- 10 (-1082) gene polymorphisms in polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 150, 61-65, 2010.10.1016/j.ejogrb.2010.02.01020189706
  127. Wang Y, Ng MC, So WY, Ma R, Ko GT, Tong PC, Chan JC. Association between tumour necrosis factor-alpha G- 308A polymorphism and risk of nephropathy in obese Chinese type 2 diabetic patients. Nephrol Dial Transplant 20, 2733-2738, 2005.10.1093/ndt/gfi10116141456
  128. Wellen KE, Hotamisligil GS. Obesity-induced inflammatory changes in adipose tissue. J Clin Invest 112, 1785-1788, 2013.10.1172/JCI2051429700614679172
  129. Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW. Effects of a polymorphism in the human tumor necrosis factor α promoter on transcriptional activation. Proc Natl Acad Sci USA 94, 3195-3199, 1997.10.1073/pnas.94.7.3195203459096369
  130. Wojta J. Platelet-derived microparticles in patients with high cardiovascular risk and subclinical atherosclerosis. Thromb Haemost 114, 1099, 2015.10.1160/TH15-09-072026467483
  131. Xavier LB, Soter MO, Sales MF, Oliveira DKD, Reis HJ, Candido AL, Reis FM, Silva IO, Gomes KB, Ferreira CN. Evaluation of PCSK9 levels and its genetic polymorphisms in women with polycystic ovary syndrome. Gene 644, 129-136, 2018.10.1016/j.gene.2017.11.00629109005
  132. Xu X, Du C, Zheng Q, Peng L, Sun Y. Effect of metformin on serum interleukin-6 levels in polycystic ovary syndrome: a systematic review. BMC Womens Health 14, 93, 2014.10.1186/1472-6874-14-93414930925096410
  133. Zhang HH, Halbleib M, Ahmad F, Manganiello VC, Greenberg AS. Tumor necrosis factor-alpha stimulates lipolysis in differentiated human adipocytes through activation of extracellular signal-related kinase and elevation of intracellular cAMP. Diabetes 51, 2929-2935, 2002.10.2337/diabetes.51.10.292912351429
  134. Zhao JL, Chen ZJ, Zhao LX, Geng L, Wang S, Gao SS, Zhang P, Liu S, Zhou FR. [Epidemiological study of clinical characteristics of Chinese Han ethnic women with polycystic ovary syndrome]. Zhonghua Fu Chan Ke Za Zhi 41, 375-379, 2006. [Article in Chinese].
  135. Zhao H, Lv Y, Li L, Chen ZJ. Genetic studies on Polycystic Ovary Syndrome. Best Pract Res Clin Obstet Gynaecol 37, 56-65, 2016.10.1016/j.bpobgyn.2016.04.00227264388
  136. Zheng SH, Li XL. Visceral adiposity index as a predictor of clinical severity and therapeutic outcome of PCOS. Gynecol Endocrinol 32, 177-183, 2016.10.3109/09513590.2015.111132726502288
  137. Zuo T, Zhu M, Xu W. Roles of oxidative stress in Polycystic Ovary Syndrome and cancers. Oxid Med Cell Longev 2016, 8589318, 2016.10.1155/2016/8589318468488826770659
DOI: https://doi.org/10.2478/enr-2018-0026 | Journal eISSN: 1336-0329 | Journal ISSN: 1210-0668
Language: English
Page range: 208 - 221
Published on: Nov 22, 2018
Published by: Slovak Academy of Sciences, Institute of Experimental Endocrinology
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year

© 2018 Laura M. L. Carvalho, Fernando M. dos Reis, Ana Lucia Candido, Fernanda F. C. Nunes, Claudia N. Ferreira, Karina B. Gomes, published by Slovak Academy of Sciences, Institute of Experimental Endocrinology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.